MISSISSAUGA, ON, September 21, 2023 – Abbott today announced an update to its latest FreeStyle Libre 2 app, which will allow Canadians who use the FreeStyle Libre 2* system to get real-time minute-by-minute glucose readings automatically† displayed on the app. With the updated mobile app, available now in the Apple App Store or Google Play Store in Canada, people can see their glucose levels and trends with a quick glance at their smartphone.× People will still have the choice to scan their phone or reader.
The new feature also allows parents and caregivers of people using the FreeStyle Libre 2 system to automatically receive glucose readings every minute and customized alarms≠ through the LibreLinkUp** caregiver app. Previously, glucose values were only delivered to the caregiver app when the FreeStyle Libre 2 sensor was scanned.
Having glucose readings every minute enables people to recognize a change in their glucose levels sooner, which can help avoid potential episodes of hyperglycemia or hypoglycemia. Effective management of diabetes is crucial as studies have shown that proper glucose control can help decrease diabetes-related complications and increase life expectancy for people living with diabetes.1,2
"People living with diabetes experience significant burden as they face the multitude of tasks required to effectively manage their diabetes," said Dr. Alice Cheng, a Toronto-based endocrinologist. "The addition of real-time readings to the FreeStyle Libre 2 system helps to lessen that burden, as users will now have greater convenience and peace of mind."
Luz Herrera, general manager of Abbott’s Diabetes Care business in Canada said: "Giving Canadians living with diabetes the ability to automatically receive their glucose information every minute can facilitate easier diabetes management, so individuals can spend more time doing the things they love. At Abbott, we are committed to ensuring our FreeStyle Libre technology not only simplifies the daily routines for people living with diabetes, but also empowers them to manage their diabetes more effectively."
To begin receiving automatic readings, people using the FreeStyle Libre 2 system will need to update their FreeStyle Libre 2 app to version 2.10.2 through the Apple App Store or to version 2.10.1 through the Google Play Store. The minute-by-minute glucose readings will be enabled when the next FreeStyle Libre 2 sensor is initiated. All users of the FreeStyle Libre 2 system will receive email and in-app notifications with information on how the update will work and make the system even easier to use.
About Abbott’s FreeStyle Libre System
Abbott’s FreeStyle Libre portfolio is the world leader in continuous glucose monitoring technology, having changed the lives of more than 5 million people across over 60 countries.3
The FreeStyle Libre continuous glucose monitoring technology consists of a sensor placed on the back of the arm for a maximum period of 14 days, and a reader or a compatible smartphone app, which displays glucose measurements.
About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.
Media Contacts:
Stacey Brown, Public Affairs
Stacey.brown2@abbott.com
ADC-79068 v1.0
Disclaimers
§ The FreeStyle Libre 2 app and the FreeStyle Libre 2 reader have similar but not identical features. Finger pricks are required if glucose readings or alarms do not match symptoms or expectations. The FreeStyle Libre 2 sensor communicates with the FreeStyle Libre 2 reader that started it or the FreeStyle Libre 2 app that started it. The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check myfreestyle.ca for more information about device compatibility before using the app. Use of FreeStyle Libre 2 may require registration with LibreView.
* The FreeStyle Libre 2 flash glucose monitoring system is indicated for measuring interstitial fluid glucose levels in people aged 4 years and older with diabetes mellitus. Always read and follow the label/insert.
† Glucose readings are automatically displayed in the FreeStyle Libre 2 app only when patients’ smartphone and sensor are connected and in range.
× The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check MyFreeStyle.ca for more information about device compatibility before using the app. Use of FreeStyle Libre 2 app may require registration with LibreView.
** The LibreLinkUp app is only compatible with certain mobile devices and operating systems. Please check www.librelinkup.com for more information about device compatibility before using the app. Use of LibreLinkUp may require registration with LibreView. The LibreLinkUp mobile app is not intended to be a primary glucose monitor: home users must consult their primary device(s) and consult a healthcare professional before making any medical interpretation and therapy adjustments from the information provided by the app.
≠ Notifications will only be received when alarms are turned on and the sensor is within 6 metres of the reading device. You must have override do not disturb settings enabled to receive alarms and alerts on your smartphone.
1 Kianmehr, Hamed, Ping Zhang, Jing Luo, Jingchuan Guo, Meda E. Pavkov, Kai McKeever Bullard, Edward W. Gregg et al. "Potential gains in life expectancy associated with achieving treatment goals in US adults with type 2 diabetes." JAMA Network Open 5, no. 4 (2022): https://doi.org/10.1001/jamanetworkopen.2022.7705
2 Imran, S. Ali, Gina Agarwal, Harpreet S. Bajaj, Stuart Ross, and Diabetes Canada Clinical Practice Guidelines Expert Committee. "Targets for glycemic control." Canadian journal of diabetes 42 (2018): S42-S46. https://doi.org/10.1016/j.jcjd.2017.10.030
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.
FOLLOW ABBOTT